Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies how well hypofractionated radiotherapy before (preoperative) or after (postoperative) breast surgery works in treating patients with different types of non-metastatic (has not spread from original tumor site) breast cancer and to determine the outcomes and side effects of this treatment. Radiation therapy is considered an integral part of breast conserving therapy. Hypofractionated radiation therapy is a radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day. This has been shown to be an effective treatment for breast cancer while reducing treatment time and decreasing side effects. Preoperative radiotherapy alone or concurrently with chemotherapy has also been tested with excellent results and with minimal toxicity. Preoperative radiation of the intact tumor with a hypofractionated regimen can potentially decrease toxicity by allowing the delivery of treatment to intact breast tissue. The potential advantages of preoperative radiation therapy include the delivery of radiation in the intact breast when radiation can be more effective as more oxygen can be available in the tissue. Furthermore, complications and cosmetic results are expected to be lower in pre-operative radiotherapy before surgery, as there have been no changes in blood supply to the breast. This lends to the possibility of using lower doses of radiotherapy to patients, and potentially better cancer associated clinical outcomes for our breast cancer patients. Undergoing hypofractionated radiation therapy before or after breast surgery may be safe and effective in treating patients with different types of non-metastatic breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby powyżej 18 roku życia.
- •Potwierdzony histopatologicznie rak piersi.
- •Rak piersi, który nie rozsiał się do innych części ciała.
- •Wskazanie do radioterapii raka piersi.
- •Zdolność do zrozumienia i podpisania świadomej zgody na udział w badaniu.
- •Możliwość wykonania wszystkich wymaganych badań i wizyt kontrolnych.
✗ Disqualifies
- •Przeciwwskazania medyczne do radioterapii.
- •Poważne choroby współistniejące, które mogłyby wpłynąć na bezpieczeństwo lub wyniki badania.
- •Ciąża.
- •Kobiety w wieku rozrodczym niestosujące skutecznej antykoncepcji.
- •Wcześniejsza radioterapia tej samej piersi lub ściany klatki piersiowej.
- •Nawrót raka piersi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- December 12, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Mayo Clinic in Arizona
Scottsdale, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.